WO2012141989A3 - Immunogens - Google Patents

Immunogens Download PDF

Info

Publication number
WO2012141989A3
WO2012141989A3 PCT/US2012/032720 US2012032720W WO2012141989A3 WO 2012141989 A3 WO2012141989 A3 WO 2012141989A3 US 2012032720 W US2012032720 W US 2012032720W WO 2012141989 A3 WO2012141989 A3 WO 2012141989A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogens
hiv
inducing
general
immune response
Prior art date
Application number
PCT/US2012/032720
Other languages
French (fr)
Other versions
WO2012141989A2 (en
Inventor
Barton F. Haynes
Guido FERRARI
Jerome Kim
Nelson MICHAEL
Original Assignee
Duke University
The Government Of The United States, As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Institute Of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University, The Government Of The United States, As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Institute Of Research filed Critical Duke University
Publication of WO2012141989A2 publication Critical patent/WO2012141989A2/en
Publication of WO2012141989A3 publication Critical patent/WO2012141989A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates, in general, to HIV and, in particular, to novel immunogens suitable for use in inducing an immune response to HIV.
PCT/US2012/032720 2011-04-09 2012-04-09 Immunogens WO2012141989A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161473748P 2011-04-09 2011-04-09
US61/473,748 2011-04-09

Publications (2)

Publication Number Publication Date
WO2012141989A2 WO2012141989A2 (en) 2012-10-18
WO2012141989A3 true WO2012141989A3 (en) 2013-01-17

Family

ID=47009920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/032720 WO2012141989A2 (en) 2011-04-09 2012-04-09 Immunogens

Country Status (1)

Country Link
WO (1) WO2012141989A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2912055A4 (en) * 2012-10-26 2016-06-08 Univ Duke Synthetic env proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213296A1 (en) * 2000-09-22 2008-09-04 Duke University Immunogen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213296A1 (en) * 2000-09-22 2008-09-04 Duke University Immunogen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHITRAPORN KARNASUTA ET AL.: "Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase 1/11 ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand", VACCINE, vol. 23, no. 19, 2005, pages 2522 - 2529 *
JOHN P. MOORE ET AL.: "Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein", JOURNAL OF VIROLOGY, vol. 70, no. 3, 1996, pages 1863 - 1872 *
SUPACHAI RERKS-NGARM ET AL.: "Vaccination with ALVAC and AIDSVAX to prevent HIV-1 Infection in Thailand", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 361, no. 23, 2009, pages 2209 - 2220, XP009141609 *

Also Published As

Publication number Publication date
WO2012141989A2 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
HK1208165A1 (en) Drug-conjugates, conjugation methods, and uses thereof
HK1212935A1 (en) Broadly-neutralizing anti-hiv antibodies hiv
IL233934A0 (en) Cd47 antibodies, compositions comprising the same and uses thereof
WO2013021279A3 (en) Highly galactosylated antibodies
EP2917360A4 (en) Antibodies to s. aureus surface determinants
WO2014083438A3 (en) Nitric oxide increasing nutritional supplements and methods
WO2012100224A3 (en) Preparation of metal-triazolate frameworks
WO2013054199A3 (en) Cmv antigens and uses thereof
CA143394S (en) Microwavable bag
CA144229S (en) Drinking flask
WO2012162534A3 (en) Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
PH12015501101A1 (en) Method for eliciting an immune response to an immunogen
WO2012109238A3 (en) Methods for increasing immune responses using agents that directly bind to and activate ire-1
CA147873S (en) Teapot
AU346731S (en) 1. Chair without arms 2. chair with arms
WO2014091167A3 (en) Cyclopropylboronic compounds, method for preparing same and use thereof
EP2720866A4 (en) Partially opaque-partially clear laminates and methods thereof.
WO2013052095A3 (en) Vaccine
WO2011101312A3 (en) Heating arrangement
EP2900693A4 (en) Adcc-mediating antibodies, combinations and uses thereof
EP2902480A4 (en) Paecilomyces variotii var. brunneolus gpp1101b, and preparation using same
GB201208384D0 (en) Vesicular formulations, uses and methods
WO2012141989A3 (en) Immunogens
WO2014009204A8 (en) Oxasilacycles and method for the production thereof
CA145238S (en) Cup for tea

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12770536

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12770536

Country of ref document: EP

Kind code of ref document: A2